GlassScriptPhysician profile
Oluwasayo Adeyemo
NPI 1205221777
$3,535.47
in general payments reported to CMS, 2019-2025
25 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.11 · 2020: $103 · 2021: $17.68 · 2022: $228 · 2023: $884 · 2024: $930 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,125.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $938.91 | 2021-2025 | Mavyret, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $547.18 | 2023-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $436.95 | 2020-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $302.70 | 2022-2025 | |
| Boston Scientific Corporation | $147.02 | 2023-2024 | Cre Pro, Wavewriter Alpha Prime 16 |
| Madrigal Pharmaceuticals | $109.69 | 2025 | Rezdiffra |
| Qol Medical, LLC | $109.61 | 2023-2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $100.91 | 2023-2024 | Dupixent |
| Pfizer INC. | $86.95 | 2024-2025 | |
| Genzyme Corporation | $81.42 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.59 | 2025 | Xifaxan |
| Sandoz INC. | $80.10 | 2023-2024 | Hyrimoz |
| Celgene Corporation | $71.26 | 2023-2024 | Zeposia |
| Medtronic, INC. | $66.38 | 2023 | Interstim |
| Lilly USA, LLC | $56.74 | 2025 | Omvoh |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $55.46 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $51.81 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $45.76 | 2019 | |
| Ironwood Pharmaceuticals, INC | $35.29 | 2023-2025 | Linzess |
| Merck Sharp & Dohme LLC | $33.89 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $23.91 | 2025 | Rebyota |
| Intercept Pharmaceuticals, INC. | $20.13 | 2020 | |
| Ardelyx, INC. | $19.74 | 2025 | Ibsrela |
| Organon LLC | $16.72 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oluwasayo Adeyemo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.